CNS Drugs

, Volume 30, Issue 1, pp 9–25 | Cite as

Abuse Potential of Pregabalin

A Systematic Review
  • Ole SchjerningEmail author
  • Mary Rosenzweig
  • Anton Pottegård
  • Per Damkier
  • Jimmi Nielsen
Systematic Review



Several case reports and epidemiological studies have raised concern about the abuse potential of pregabalin, the use of which has increased substantially over the last decade. Pregabalin is, in some cases, used for recreational purposes and it has incurred attention among drug abusers for causing euphoric and dissociative effects when taken in doses exceeding normal therapeutic dosages or used by alternative routes of administration, such as nasal insufflation or venous injection. The magnitude of the abuse potential and the mechanism behind it are not fully known.


The aim of this study was to present a systematic review of the data concerning the abuse potential of pregabalin.


We performed a systematic literature search and reviewed the preclinical, clinical and epidemiological data on the abuse potential of pregabalin.


We included preclinical (n = 17), clinical (n = 19) and epidemiological (n = 13) studies addressing the abuse potential of pregabalin. We also reviewed case reports (n = 9) concerning abuse of pregabalin. The preclinical studies indicated that pregabalin possesses modulatory effects on the GABA and glutamate systems, leaving room for an abuse potential. Further, clinical studies reported euphoria as a frequent side effect in patients treated with pregabalin. The majority of case reports concerning abuse of pregabalin involved patients with a history of substance abuse and, similarly, epidemiological studies found evidence of abuse, especially among opiate abusers.


Overall, the available literature suggests an important clinical abuse potential of pregabalin and prescribers should pay attention to signs of abuse, especially in patients with a history of substance abuse.


Gabapentin Pregabalin Conditioned Place Preference Withdrawal Symptom Abuse Potential 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Compliance with Ethical Standards


No sources of funding were used to assist with the preparation for this paper.

Conflict of interest

Ole Schjerning has received speaker honoraria from Lundbeck. Jimmi Nielsen has received research grants from Lundbeck, Pfizer and speakers honoraria from Hemocue, Lundbeck and Bristol Myers Squibb. Anton Pottegård, Mary Rosenzweig and Per Damkier state no conflicts of interest.


  1. 1.
    Montgomery S, Emir B, Haswell H, Prieto R. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability. Curr Med Res Opin. 2013;29:1223–30.PubMedCrossRefGoogle Scholar
  2. 2.
    de Guglielmo G, Cippitelli A, Somaini L, Gerra G, Li H, Stopponi S, et al. Pregabalin reduces cocaine self-administration and relapse to cocaine seeking in the rat. Addict Biol. 2013;18:644–53.PubMedCrossRefGoogle Scholar
  3. 3. Institute for Health Data and Disease Control. Usage data on Lyrica. 2014. Accessed 29 Nov 2014.
  4. 4.
    Pharma Marketing. Top 50 pharmaceutical products by global sales. 2015. Accessed 28 Oct 2015.
  5. 5.
    Wettermark B, Brandt L, Kieler H, Boden R. Pregabalin is increasingly prescribed for neuropathic pain, generalised anxiety disorder and epilepsy but many patients discontinue treatment. Int J Clin Pract. 2014;68:104–10.PubMedCrossRefGoogle Scholar
  6. 6.
    Cho YW, Song ML. Effects of pregabalin in patients with hypnotic-dependent insomnia. J Clin Sleep Med. 2014;10:545–50.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Oulis P, Kalogerakou S, Anyfandi E, Konstantakopoulos G, Papakosta VM, Masdrakis V, et al. Cognitive effects of pregabalin in the treatment of long-term benzodiazepine-use and dependence. Hum Psychopharmacol. 2014;29:224–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Guglielmo R, Martinotti G, Clerici M, Janiri L. Pregabalin for alcohol dependence: a critical review of the literature. Adv Ther. 2012;29:947–57.PubMedCrossRefGoogle Scholar
  9. 9.
    Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011;52:826–36.PubMedCrossRefGoogle Scholar
  10. 10.
    Halaby A, Kassm SA, Naja WJ. Pregabalin dependence: a case report. Curr Drug Saf. 2015;10:184–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Grosshans M, Lemenager T, Vollmert C, Kaemmerer N, Schreiner R, Mutschler J, et al. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol. 2013;69:2021–5.PubMedCrossRefGoogle Scholar
  12. 12.
    European Medicine Agency. Summary of product characteristics for pregabalin. 2014. Accessed 29 Nov 2014.
  13. 13.
    Expert P. Abuse liability assessment of CNS drugs: conclusions, recommendations, and research priorities. Drug Alcohol Depend. 2003;70(3 Suppl.):S107–14.Google Scholar
  14. 14.
    Balster RL, Bigelow GE. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend. 2003;70:S13–40.PubMedCrossRefGoogle Scholar
  15. 15.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Smith SM, Dart RC, Katz NP, Paillard F, Adams EH, Comer SD, et al. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154:2287–96.PubMedCrossRefGoogle Scholar
  17. 17.
    Center for Drug Evaluation and Research US. Consult on abuse potential for NDA review, Lyrica (Pregabalin). In: FaDAP, editor. Review. USA: US Food and Drug Administration; 2004.Google Scholar
  18. 18.
    Andrews N, Loomis S, Blake R, Ferrigan L, Singh L, McKnight AT. Effect of gabapentin-like compounds on development and maintenance of morphine-induced conditioned place preference. Psychopharmacology (Berl). 2001;157:381–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Rutten K, De Vry J, Robens A, Tzschentke TM, van der Kam EL. Dissociation of rewarding, anti-aversive and anti-nociceptive effects of different classes of anti-nociceptives in the rat. Eur J Pain. 2011;15:299–305.PubMedCrossRefGoogle Scholar
  20. 20.
    Stopponi S, Somaini L, Cippitelli A, de Guglielmo G, Kallupi M, Cannella N, et al. Pregabalin reduces alcohol drinking and relapse to alcohol seeking in the rat. Psychopharmacology (Berl). 2012;220:87–96.PubMedCrossRefGoogle Scholar
  21. 21.
    Becker HC, Myrick H, Veatch LM. Pregabalin is effective against behavioral and electrographic seizures during alcohol withdrawal. Alcohol Alcohol. 2006;41:399–406.PubMedCrossRefGoogle Scholar
  22. 22.
    Aracil-Fernandez A, Almela P, Manzanares J. Pregabalin and topiramate regulate behavioural and brain gene transcription changes induced by spontaneous cannabinoid withdrawal in mice. Addict Biol. 2013;18:252–62.PubMedCrossRefGoogle Scholar
  23. 23.
    Hasanein P, Shakeri S. Pregabalin role in inhibition of morphine analgesic tolerance and physical dependency in rats. Eur J Pharmacol. 2014;742:113–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr, Sharma U, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9:792–805.PubMedCrossRefGoogle Scholar
  25. 25.
    Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264–73.PubMedCrossRefGoogle Scholar
  26. 26.
    Ohta H, Oka H, Usui C, Ohkura M, Suzuki M, Nishioka K. A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia. Arthritis Res Ther. 2012;14:R217.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP Jr, Martin SA, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35:502–14.PubMedGoogle Scholar
  28. 28.
    Nasser K, Kivitz AJ, Maricic MJ, Silver DS, Silverman SL. Twice daily versus once nightly dosing of pregabalin for fibromyalgia: a double-blind randomized clinical trial of efficacy and safety. Arthritis Care Res (Hoboken). 2014;66:293–300.PubMedCrossRefGoogle Scholar
  29. 29.
    Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63:2104–10.PubMedCrossRefGoogle Scholar
  30. 30.
    Atalay H, Solak Y, Biyik Z, Gaipov A, Guney F, Turk S. Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients. Clin Drug Investig. 2013;33:401–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008;8:33.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Stacey BR, Barrett JA, Whalen E, Phillips KF, Rowbotham MC. Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. J Pain. 2008;9:1006–17.PubMedCrossRefGoogle Scholar
  33. 33.
    Simpson DM, Schifitto G, Clifford DB, Murphy TK, Durso-De Cruz E, Glue P, et al. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology. 2010;74:413–20.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Gilron I, Wajsbrot D, Therrien F, Lemay J. Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial. Clin J Pain. 2011;27:185–93.PubMedCrossRefGoogle Scholar
  35. 35.
    Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 2003;160:533–40.PubMedCrossRefGoogle Scholar
  36. 36.
    Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2005;25:151–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Allen R, Chen C, Soaita A, Wohlberg C, Knapp L, Peterson BT, et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med. 2010;11:512–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Olesen SS, Bouwense SA, Wilder-Smith OH, van Goor H, Drewes AM. Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial. Gastroenterology. 2011;141:536–43.PubMedCrossRefGoogle Scholar
  39. 39.
    Chew ML, Alvey CW, Plotka A, Pitman VW, Alebic-Kolbah T, Scavone JM, et al. Pregabalin controlled-release pharmacokinetics in healthy volunteers: analysis of four multiple-dose randomized clinical pharmacology studies. Clin Drug Investig. 2014;34:627–37.PubMedCrossRefGoogle Scholar
  40. 40.
    Lang N, Sueske E, Hasan A, Paulus W, Tergau F. Pregabalin exerts oppositional effects on different inhibitory circuits in human motor cortex: a double-blind, placebo-controlled transcranial magnetic stimulation study. Epilepsia. 2006;47:813–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Chua YC, Ng KS, Sharma A, Jafari J, Surguy S, Yazaki E, et al. Randomised clinical trial: pregabalin attenuates the development of acid-induced oesophageal hypersensitivity in healthy volunteers—a placebo-controlled study. Aliment Pharmacol Ther. 2012;35:319–26.PubMedCrossRefGoogle Scholar
  42. 42.
    Chew ML, Plotka A, Alvey CW, Pitman VW, Alebic-Kolbah T, Scavone JM, et al. Pharmacokinetics of pregabalin controlled-release in healthy volunteers: effect of food in five single-dose, randomized, clinical pharmacology studies. Clin Drug Investig. 2014;34:617–26.PubMedCrossRefGoogle Scholar
  43. 43.
    Filipetto FA, Zipp CP, Coren JS. Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc. 2010;110:605–7.PubMedGoogle Scholar
  44. 44.
    Grosshans M, Mutschler J, Hermann D, Klein O, Dressing H, Kiefer F, et al. Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiatry. 2010;167:869.PubMedCrossRefGoogle Scholar
  45. 45.
    Westin AA, Strom EJ. Yes, pregabalin can be abused! Tidsskr Nor Laegeforen. 2010;130:2108.PubMedCrossRefGoogle Scholar
  46. 46.
    Yargic I, Ozdemiroglu FA. Pregabalin abuse: a case report/Pregabalin kötüye kullanımı: Bir olgu sunumu. Bull Clin Psychopharmacol. 2011;21:64–6.CrossRefGoogle Scholar
  47. 47.
    Skopp G, Zimmer G. Pregabalin—a drug with abuse potential? Arch Kriminol. 2012;229:44–54.PubMedGoogle Scholar
  48. 48.
    Carrus D, Schifano F. Pregabalin misuse-related issues; intake of large dosages, drug-smoking allegations, and possible association with myositis: two case reports. J Clin Psychopharmacol. 2012;32:839–40.PubMedCrossRefGoogle Scholar
  49. 49.
    Papazisis G, Garyfallos G, Sardeli C, Kouvelas D. Pregabalin abuse after past substance-seeking behavior. Int J Clin Pharmacol Ther. 2013;51:441–2.PubMedCrossRefGoogle Scholar
  50. 50.
    Gahr M, Franke B, Freudenmann RW, Kolle MA, Schonfeldt-Lecuona C. Concerns about pregabalin: further experience with its potential of causing addictive behaviors. J Addict Med. 2013;7:147–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Landmark CJ, Fossmark H, Larsson PG, Rytter E, Johannessen SI. The prescription registry and abuse of pregabalin. Tidsskr Nor Laegeforen. 2011;131:223.PubMedCrossRefGoogle Scholar
  52. 52.
    Boden R, Wettermark B, Brandt L, Kieler H. Factors associated with pregabalin dispensing at higher than the approved maximum dose. Eur J Clin Pharmacol. 2014;70:197–204.PubMedCrossRefGoogle Scholar
  53. 53.
    Kapil V, Green JL, Le Lait M-C, Wood DM, Dargan PI. Misuse of the γ-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. Br J Clin Pharmacol. 2014;78:190–1.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Schwan S, Sundstrom A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin–results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol. 2010;66:947–53.PubMedCrossRefGoogle Scholar
  55. 55.
    Gahr M, Freudenmann RW, Hiemke C, Kolle MA, Schonfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol. 2013;69:1335–42.PubMedCrossRefGoogle Scholar
  56. 56.
    Wills B, Reynolds P, Chu E, Murphy C, Cumpston K, Stromberg P, et al. Clinical outcomes in newer anticonvulsant overdose: a poison center observational study. J Med Toxicol. 2014;10:254–60.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Baird CR, Fox P, Colvin LA. Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers. Eur Addict Res. 2014;20:115–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Jonsson B, Backman E, Salmonson H, Hojer J. Injection of crushed tablets–a prospective observational study. Clin Toxicol (Phila). 2014;52:982–3.PubMedCrossRefGoogle Scholar
  59. 59.
    Kriikku P, Wilhelm L, Rintatalo J, Hurme J, Kramer J, Ojanpera I. Pregabalin serum levels in apprehended drivers. Forensic Sci Int. 2014;243:112–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Wilens T, Zulauf C, Ryland D, Carrellas N, Catalina-Wellington I. Prescription medication misuse among opioid dependent patients seeking inpatient detoxification. Am J Addict. 2014;24:173–7.CrossRefGoogle Scholar
  61. 61.
    Hakkinen M, Vuori E, Kalso E, Gergov M, Ojanpera I. Profiles of pregabalin and gabapentin abuse by postmortem toxicology. Forensic Sci Int. 2014;241:1–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Launiainen T, Broms U, Keskitalo-Vuokko K, Pitkaniemi J, Pelander A, Kaprio J, et al. Nicotine, alcohol, and drug findings in young adults in a population-based postmortem database. Nicotine Tob Res. 2011;13:763–71.PubMedCrossRefGoogle Scholar
  63. 63.
    Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73:137–50.PubMedCrossRefGoogle Scholar
  64. 64.
    Filip M, Frankowska M, Sadakierska-Chudy A, Suder A, Szumiec L, Mierzejewski P, et al. GABAB receptors as a therapeutic strategy in substance use disorders: focus on positive allosteric modulators. Neuropharmacology. 2015;88:36–47.PubMedCrossRefGoogle Scholar
  65. 65.
    Vlachou S, Markou A. GABAB receptors in reward processes. Adv Pharmacol. 2010;58:315–71.PubMedCrossRefGoogle Scholar
  66. 66.
    Tan KR, Brown M, Labouebe G, Yvon C, Creton C, Fritschy JM, et al. Neural bases for addictive properties of benzodiazepines. Nature. 2010;463:769–74.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Errante LD, Petroff OA. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure. 2003;12:300–6.PubMedCrossRefGoogle Scholar
  68. 68.
    Navarrete F, Perez-Ortiz JM, Manzanares J. Pregabalin- and topiramate-mediated regulation of cognitive and motor impulsivity in DBA/2 mice. Br J Pharmacol. 2012;167:183–95.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    European Medicine Agency (EMA). Scientific discussion—Lyrica. In: Agency EM, editor. European Medicines Agency. 2005. Accessed 28 Nov 2015.
  70. 70.
    Arnold LM, Arsenault P, Huffman C, Patrick JL, Messig M, Chew ML, et al. Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study. Curr Med Res Opin. 2014;30:2069–83.PubMedCrossRefGoogle Scholar
  71. 71.
    Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49:661–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Bockbrader HN, Radulovic LL, Posvar EL, Strand JC, Alvey CW, Busch JA, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol. 2010;50:941–50.PubMedCrossRefGoogle Scholar
  73. 73.
    Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004;24:141–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Sugandiran NBJ. Pregabalin may cause dependence even if it is not abused. Arc Cas Rep CMed. 2014;1:1.Google Scholar
  75. 75.
    Chalabianloo F, Schjott J. Pregabalin and its potential for abuse. Tidsskr Nor Laegeforen. 2009;129:186–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Hallas J, Nissen A. Individualized drug utilization statistics. Analysing a population’s drug use from the perspective of individual users. Eur J Clin Pharmacol. 1994;47:367–72.PubMedCrossRefGoogle Scholar
  77. 77.
    Hallas J, Stovring H. Templates for analysis of individual-level prescription data. Basic Clin Pharmacol Toxicol. 2006;98:260–5.PubMedCrossRefGoogle Scholar
  78. 78.
    Schifano F, D’Offizi S, Piccione M, Corazza O, Deluca P, Davey Z, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011;80:118–22.PubMedCrossRefGoogle Scholar
  79. 79.
    Bramness JG. Abuse of pregabalin. Tidsskr Nor Laegeforen. 2010;130:1703–4.PubMedCrossRefGoogle Scholar
  80. 80.
    Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014;28:491–6.PubMedCrossRefGoogle Scholar
  81. 81.
    Papazisis G, Tzachanis D. Pregabalin’s abuse potential: a mini review focusing on the pharmacological profile. Int J Clin Pharmacol Ther. 2014;52:709–16.PubMedCrossRefGoogle Scholar
  82. 82.
    Baastrup C, Jensen TS, Finnerup NB. Pregabalin attenuates place escape/avoidance behavior in a rat model of spinal cord injury. Brain Res. 2011;1370:129–35.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of PsychiatryAalborg University HospitalAalborgDenmark
  2. 2.Department of Clinical MedicineAalborg UniversityAalborgDenmark
  3. 3.Danish Health and Medicines AuthorityCopenhagenDenmark
  4. 4.Clinical Pharmacology, Department of Public HealthUniversity of Southern DenmarkOdenseDenmark
  5. 5.Department of Clinical Chemistry and PharmacologyOdense University HospitalOdenseDenmark
  6. 6.Centre for SchizophreniaAalborgDenmark

Personalised recommendations